{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:35:32Z","timestamp":1792740932271,"version":"4.5.0"},"reference-count":20,"publisher":"Centers for Disease Control MMWR Office","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6441a3","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T15:44:31Z","timestamp":1445528671000},"page":"1171-1176","source":"Crossref","is-referenced-by-count":198,"title":["Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015"],"prefix":"10.15585","volume":"64","author":[{"given":"Jessica R.","family":"MacNeil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorry","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Folaranmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael R.","family":"Ortega-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R1","unstructured":"Accelerated approval of new drugs for serious or life-threatening illnesses, 21 C.F.R. Sect. 314.500 (2015). Available at http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R2","doi-asserted-by":"crossref","unstructured":"Bhuyan P, Eiden J, Jones TR, Immunogenicity of human papilloma vaccine coadministered with an investigational bivalent rLP2086 vaccine against meningococcal serogroup B in healthy adolescents. Philadelphia, PA: IDWeek; 2014. Available at http:\/\/ofid.oxfordjournals.org\/content\/1\/suppl_1\/S317.2.full?sid=25a2b12f-c211-4ecc-bb47-e6ceba7bb4a2.","DOI":"10.1093\/ofid\/ofu052.789"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R4","doi-asserted-by":"crossref","unstructured":"Vesikari T, Ostergaard L, Diez-Domingo J, Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc; 2015. Available at http:\/\/jpids.oxfordjournals.org\/content\/early\/2015\/08\/03\/jpids.piv039.full.","DOI":"10.1093\/jpids\/piv039"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R5","doi-asserted-by":"crossref","unstructured":"Vesikari T, Wysocki J, Kieninger D, Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine to healthy adolescents. In: Proceedings of the 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases; May 6\u201316, 2014, Dublin, Ireland.","DOI":"10.1093\/jpids\/piv064"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R6","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R7","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","article-title":"Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study.","volume":"33","author":"Perrett","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R9","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R11","unstructured":"Advisory Committee on Immunization Practices (ACIP). Evidence-based recommendations\u2014GRADE. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at http:\/\/www.cdc.gov\/vaccines\/acip\/recs\/GRADE\/about-grade.html."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R12","unstructured":"Advisory Committee on Immunization Practices (ACIP). GRADE evidence tables\u2014recommendations in MMWR. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at http:\/\/www.cdc.gov\/vaccines\/acip\/recs\/GRADE\/table-refs.html."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R13","unstructured":"Food and Drug Administration. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Washington, DC: Food and Drug Administration; 2011. Available at http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM248586.pdf."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R14","doi-asserted-by":"crossref","first-page":"e01625","DOI":"10.1128\/mBio.01625-14","article-title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.","volume":"5","author":"Costa","year":"2014","journal-title":"MBio"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R15","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/infdis\/jiv081","article-title":"Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine.","volume":"212","author":"Granoff","year":"2015","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R16","unstructured":"Food and Drug Administration. Trumenba Biologics license application. Washington, DC: Food and Drug Administration; 2014. Available at http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM424626.pdf."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R17","unstructured":"Food and Drug Administration. Bexsero Biologics license application. Washington, DC: Food and Drug Administration; 2014. Available at http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM434714.pdf."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R18","unstructured":"Food and Drug Administration. Trumenba US package insert. Washington, DC: Food and Drug Administration; 2014. Available at http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM421139.pdf."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R19","unstructured":"Food and Drug Administration. Bexsero US package insert. Washington, DC: Food and Drug Administration; 2015. Available at http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM431447.pdf."},{"key":"key-10.15585\/mmwr.mm6441a3-201510221144-R20","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T22:19:50Z","timestamp":1653344390000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6441a3.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":20,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2015,10,23]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6441a3","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,23]]}}}